This is the text extract for Tender of Certain Pharmaceuticals, browse documents here.
14 September 2007 TO: MEDICAL GROUPS, DHB HOSPITAL PHARMACIES AND INTERESTED PARTIES CONSULTATION ON TENDER OF CERTAIN PHARMACEUTICALS ALL RESPONSES DUE BY 5PM, 26 OCTOBER 2007 In accordance with PHARMAC’s objective of securing for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided, PHARMAC is consulting on the possibility of tendering for Sole Subsidised Supply and/or Hospital Supply Status of certain pharmaceuticals listed in Schedule One of this document. Attached to this letter is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB Hospital pharmacies. Pharmaceuticals are listed alphabetically by chemical, form and strength in therapeutic groups and have a ‘C’ and/or ‘H’ next to them to indicate whether they are being tendered for community and/or hospital supply. In general, the proposed Tender process would be similar to the 2006/07 Tender. A copy of the 2006/07 Invitation to Tender is available either on our website: www.pharmac.govt.nz, or by contacting PHARMAC. Comments Sought We seek comments on the approach outlined in the following pages, in particular the following: · · · · the proposed process and timetable; the actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One; and for hospital pharmaceuticals what the appropriate Discretionary Variance Limit for each pharmaceutical would be, where a 1% Discretionary Variance Limit is considered clinically unacceptable; and comments on a proposal for Sole Subsidised Supply to include access to funding for alternative brands (Alternative Brand Access).
Background Since 1997 PHARMAC has been using the strategy of tendering for sole supply of pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of off patent pharmaceuticals. It is proposed that the community Tender and hospital Tender processes continue to be run in unison, however the pharmaceutical list for community and hospital pharmacies may be different.
A150080 - qA7633
1
Key Aspects of Awarding a Tender for Community Pharmaceuticals: · For the community pharmaceuticals the Tender winning brand would be the only subsidised brand for approximately 2½ years. The Sole Subsidised Supply period would conclude on 30 June 2011 for all awarded Tenders. The Sole Subsidised Supply brand would be fully subsidised for the Tender period which means a pharmaceutical that currently carries a manufacturer’s surcharge (that is the additional patient charge above that of the patient copayment), would become fully subsidised if a Tender was awarded. No other brand of the pharmaceutical could be listed (or subsidised) on the Pharmaceutical Schedule during the Tender period (subject to any Alternative Brand Access, as proposed). Other brands could continue to be marketed, sold and dispensed in New Zealand, however they would not receive a Government subsidy.
·
·
·
Key Aspects of Awarding a Tender for the DHB Hospital Pharmaceuticals:
·
For the DHB Hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (excluding any allowance for alternative brands under the agreed Discretionary Variance Limits) for approximately 2½ years. The Hospital Supply Status period would conclude on 30 June 2011 for all awarded Tenders. No other brand of the pharmaceutical would be listed (or purchased) on Section H of the Pharmaceutical Schedule during the Tender period except as allowed under any DV Limits.
·
The Process The Tender process is run annually. The proposed timelines for the 2007/08 Tender are as follows:
Date September/October 2007 26 October 2007 November 2007 Late December 2007 Late February 2008 From April 2008 30 June 2011 Event Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender. Final date for all consultation to be received. Meeting of Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list. Issuing of the 2006/07 Invitation to Tender. Invitation to Tender closes. Board decisions on the first Tender winners announced. End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2007/08 Tender. Terms after the End Date may apply.
Unresolved Tender Bids PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 22 December 2005 (2005/06 Tender) and the Invitation to Tender dated 15 December 2006 (2006/07 Tender) prior to issuing the 2007/08 Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in December 2007. Any unresolved Tender Bids have not been included in the draft pharmaceutical list.
A150080 - qA7633
2
Contractual obligations for suppliers A copy of the draft contractual requirements which would form the terms of the contract with successful suppliers in the 2007/08 Tender is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50. The following proposed changes to the Invitation to Tender should be noted: This year PHARMAC proposes to introduce an electronic tendering system that suppliers would be required to use in order to submit a Tender Bid(s). Alternative Brand Access This year we are also consulting on adding an allowance within the Tender contract for PHARMAC to provide funding for alternative brands of community pharmaceuticals (called Alternative Brand Access). This is a change from previous years’ tenders, and if adopted would create a new mechanism for people to access brands of a medicine other than the one that wins the tender contract. If the contractual allowance for Alternative Brand Access is adopted it would necessarily result in some changes to the manner in which Sole Subsidised Supply operates. As well as comments on the proposal in general, we seek particular consideration of the following questions: · · Should we allow the provision of a subsidy for an alternative brand and, if so, in what circumstances? What percentage allowance for alternative brands should be included within tender bids?
Background Between 1997 and 2007 over $300 million that would otherwise have been unavailable has been reinvested in new pharmaceuticals and other health services as a result of sole-supply tenders. Tenders and RFPs encourage competition so that the value from pharmaceuticals is maximised (including the costs of continuous supply being underwritten). Sole Subsidised Supply for a defined period of time is often used to generate this competition. Once Sole Subsidised Supply is awarded all other brands of that pharmaceutical are delisted from the Pharmaceutical Schedule, and are no longer subsidised. It may be desirable, where identified as a need by PTAC (and/or relevant subcommittee), to have greater flexibility under the sole supply policy for people to access other brands when the tender-winning brand is clinically unsuitable. Alternative Brand Access recognises that while most generic products will have established “bioequivalence” to the current market leader, in some circumstances a small number of patients may experience difficulties with the change. Currently the mechanism available for funding of alternative brands, where one brand holds Sole Subsidised Supply, is through the Community Exceptional Circumstances (CEC) process. Given its specific criteria and purpose, the CEC process typically provides funding for alternative brands very infrequently.
A150080 - qA7633
3
Possible mechanism for implementation To enable the proposed tender contractual changes to be developed, PHARMAC has considered possible mechanisms to apply an Alternative Brand Access. We are proposing the following mechanism: · The product list would contain an Authorised Allowance which would be the amount of an Alternative Brand of a particular pharmaceutical that could be subsidised without reimbursement to the tender winner for the reduced volume. An allowance in the region of 0.2 - 1% may be appropriate (where applied at all), although we welcome other views. PHARMAC would seek advice from PTAC and/or its relevant subcommittee on whether to include an allowance in each case. The access to funding for the alternative brand would be through a Special Authority, on an “access by application” basis. Applications would be considered by a panel of practicing clinicians, using the following criteria, or similar:
Evidence is provided by the patient’s doctor that: a. The patient was adequately managed on a previously subsidised brand, and the subsidy for that brand is being removed as a result of Sole Subsidised Supply; and b. There are no other suitable alternative pharmaceuticals, or all the alternatives (including dose adjustment) have had an adequate trial and failed; and c. The Sole Subsidised Supply brand is considered to be unsuitable because of: i. A serious adverse reaction has occurred to the Sole Subsidised Supply brand ; or ii. An excipient in the Sole Subsidised contraindicated in the patient; or Supply brand that is
·
· ·
iii. Lack of efficacy or intolerable side effects to the Sole Subsidised Supply brand that persist through an adequate trial of the subsidised brand, followed by reappearance of the issue on re-challenge. Approvals would not be given for issues related to features of the product that were considered as part of the tender evaluation (e.g. physical features of the product such as flavour, coatings etc.), and would not be given if the issue arose more than 6 months after the initiation of the Sole Subsidised Supply period.
·
The funding for an alternative brand would be provided on a “Cost Brand Source” basis, meaning that funding could be provided even if the product had to be sourced from overseas (i.e. if the local supplier had discontinued supply).
Lead Time We propose to amend the Lead Time so that it is clear that the quoted Lead Time means that stock would be available to the market on the 12th prior the listing date in
A150080 - qA7633
4
the Pharmaceutical Schedule (see proposed definition of Lead Time in clause 1 of Schedule 1 of the Invitation). Financial compensation for breach of DV limits PHARMAC proposes to amend the minimum payment required of a DHB that breaches its DV limits, where the national DV limit has been breached, from $5,000 per tender item to $1,000 per tender item. Reference Pricing Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s). The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to two possible scenarios where: 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup. 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others. Both scenarios could give rise to new or increased manufacturer surcharges. Distribution of Consultation Documents Please note that this consultation letter has been widely distributed however should you consider that a particular person, group or agency should receive this and future Tender documents please feel free to contact PHARMAC (also available from our website). We also invite any person or group to contact PHARMAC should you wish to have a meeting to discuss this consultation document. Please direct any queries you may have to Mike Bignall (DDI: (04) 9167 562) at PHARMAC for questions in relation to community supply, and Andrew Davies (DDI: (04) 9167 531) for questions in relation to hospital supply. Yours sincerely
Steffan Crausaz Manager, Funding and Procurement
A150080 - qA7633 5
Possible pharmaceuticals for tender for sole supply
Order of pharmaceuticals in this Annex The pharmaceuticals have been listed in therapeutic groups according to the classification system used in the Pharmaceutical Schedule. Below is a list of the groups, and the corresponding page numbers for your ease of reference. Please note that pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one.
Therapeutic Group Alimentary Tract and Metabolism Blood and Blood Forming Organs Cardiovascular System Dermatologicals Extemporaneously Compounded Preparations Genito-Urinary System Hormone Preparations – Systemic excluding contraceptives Infections – Agents for Systemic Use Musculoskeletal System Nervous System Oncology and Immunosuppressants Respiratory System and Allergies Sensory Organ Special Foods Page Numbers 8 – 10 10 – 12 12 – 14 14 – 17 17 17 17 – 19 19 – 23 23 – 24 24 – 29 29 – 31 31 31 – 33 33
Information provided for each pharmaceutical For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information: · · · · the current ex-manufacturer subsidy per unit of measure as at 1 September 2007; number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2007; estimated annual community market value at current subsidies; and comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.
The figures for the number of units subsidised in community pharmacies are approximate and are based on the year ending June 2007. These figures are indicative only and sales are not guaranteed. PHARMAC makes no representation as to the level of sales or likely sales of any tender item. There are no figures available for hospital pharmaceuticals. We have estimated market value by multiplying the volume of units subsidised in the year ending 30 June 2007 by the relevant listed unit subsidy as at 1 September 2007.
A150080 - qA7633
7
Patents A number of pharmaceuticals included in this list may still be on patent. Based on information available to PHARMAC, we believe these patents will expire by within the sole supply period. While PHARMAC has taken care in preparing the information contained in this table, it does not make any representation as to the accuracy of this information and accepts no liability in the event that the information is incorrect. Suppliers remain responsible for ensuring they do not infringe patents. Suppliers are responsible for their own independent assessment of the information and must decide for themselves whether or not to make an investment and on what terms. Explanation of terms, symbols and abbreviations Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed. The following table explains the symbols used in the draft pharmaceutical list:
Symbol Underline C H PCT + * Explanation Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2008 unless otherwise stated in the Comments column and a listing of a new brand could only occur until after that date. To be tendered for Sole Subsidised Supply (community pharmaceuticals). To be tendered for Hospital Supply Status (DHB Hospital pharmaceuticals). A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project. PHARMAC has been advised of the existence of a process patent. There is no fully funded product available for this line item (in relation to community supply).
A150080 - qA7633
8
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Units Cost Unit Subsidy DV Limit Comments
Alimentary Tract and Metabolism
Acarbose Tab 50 mg Tab 100 mg Alfacalcidol Cap 0.25 mcg Cap 1 mcg Oral drops 2 mcg per ml Amphotericin B Lozenges 10 mg Oral liq 100 mg per ml 281,820 $82,573 $0.2930 C H C H 1% 1%
Not currently listed in the Pharmaceutical Schedule
475,805 168,940
$116,287 $58,183
$0.2444 $0.3444
C H C H
1% 1%
159,315 41,315 7,125
$41,932 $36,349 $21,617
$0.2632 $0.8798 $3.0340
C H C H C H
1% 1% 1%
Budesonide Cap 3 mg Calcium Eff tab 1 g 3,300,309 $821,777 $0.2490 C H 1%
Additional additives would be considered. Dose range of 1 g of elemental calcium is required
43,445
$80,373
$1.8500
C H
1%
Calcium Carbonate Tab 1.25 g Tab 1.5 g Calcium Carbonate with Aminoacetic Acid Tab 420 mg with aminoacetic acid 180 mg Calcium Gluconate Inj 10%, 10 ml Danthron With Poloxamer Cap 25 mg with poloxamer 200 mg Cap 37.5 mg with poloxamer 500 mg C H C H 1% 1%
Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule
32,067,230 5,095,250
$1,176,867 $210,434
$0.0367 $0.0413
C H C H
1% 1%
1,359,384
$40,782
$0.0300
*
C H
1%
1,225
$2,621
$2.1398
C H
1%
Diphenoxylate Hydrochloride with Atropine Sulphate Tab 2.5 mg with atropine sulphate 25 mcg Docusate Sodium Tab 50 mg Tab 120 mg Ferrous Salts Tab 6,953,179 C H 1%
Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required (short-acting or long-acting)
757,691
$29,550
$0.0390
C H
1%
791,187 1,292,250
$38,689 $62,028
$0.0489 $0.0480
C H C H
1% 1%
8
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Ferrous Salts with Folic Acid Tab with folic acid 1,001,377 $60,083 $0.0600 * C H 1%
Any iron salt would be considered. Dose range of 60 - 110 mg elemental iron per tablet required (shortacting or long-acting)
Units
Cost
Unit Subsidy
DV Limit
Comments
Glibenclamide Tab 2.5 mg Tab 5 mg Gliclazide Tab 80 mg Glipizide Tab 5 mg Glucose Oxidase Urine Ketone Diagnostic Test * C
Each individual product should be foil wrapped
418,451 1,758,731
$15,817 $58,214
$0.0378 $0.0331
C H C H
1% 1%
18,260,202
$1,331,169
$0.0729
C H
1%
13,016,532
$455,579
$0.0350
C H
1%
Hyoscine N-Butylbromide Inj 20 mg, 1 ml Tab 10 mg Iron Polymaltose Inj 50 mg per ml, 2 ml Magnesium Hydroxide Tab C H 1%
Not currently listed in the Pharmaceutical Schedule
56,467 2,600,409
$80,748 $172,927
$1.4300 $0.0665 *
C H C H
1% 1%
18,951
$113,516
$5.9900
C H
1%
Mebeverine Hydrochloride Tab 135 mg Nystatin Oral liq 100,000 u per ml Olsalazine Cap 250 mg Tab 500 mg Poloxamer Oral drops 10% $0.1310 C H 1%
Not currently listed in the Pharmaceutical Schedule
674,683
$80,355
$0.1191
*
C H
1%
1,027,781
$129,809
$0.1263
C H
1%
206,994 177,677
$65,224 $106,357
$0.3151 $0.5986
C H C H
1% 1%
Ranitidine Hydrochloride Inj 25 mg per ml, 2 ml Tab 150 mg Tab 300 mg Simethicone Oral liq aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg per 5 ml Sodium Alginate Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml 7,603,083 $22,809 $0.0030 * C H 1%
Additional active agents would be accepted 9
3,008 6,093,289 1,948,336
$5,264 $194,985 $85,337
$1.7500 $0.0320 $0.0438
C H C H C H
1% 1% 1%
12,475,721
$37,427
$0.0030
*
C H
1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Sodium Bicarbonate Tab C H 1%
Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
Sodium Cromoglycate Cap 100 mg Sucralfate Tab 1 g Tolbutamide Tab 500 mg Triamcinolone Acetonide 0.1% in Dental Paste USP Ursodeoxycholic Acid Cap 250 mg - 300 mg 272,261 $735,050 $2.6998 C H 1%
Bids would be accepted for a tablet within this strength range
82,948
$73,998
$0.8921
C H
1%
70,271
$20,786
$0.2958
*
C H
1%
128,075
$15,369
$0.1200
C H
1%
86,085
$77,477
$0.9000
C H
1%
Vitamin A with Vitamins D and C Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops Zinc Sulphate Cap 220 mg 432,069 $38,886 $0.0900 C H 1% 154,883 $67,839 $0.4380 * C H 1%
Blood and Blood Forming Organs
Acipimox Cap 250 mg Aprotinin Inj 10,000 mcg per ml, 50 ml Inj 10,000 mcg per ml, 100 ml Inj 10,000 mcg per ml, 200 ml 343 $21,815 $63.6000 * C H C H C H 1% 1% 1%
Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule
227,496
$142,185
$0.6250
C H
1%
Bezafibrate Tab 200 mg Calcium Polystyrene Sulphonate Powder Cholestyramine with Aspartame Sachets 4 g with aspartame Dextrose Inj 50%, 10 ml Dipyridamole Tab 25 mg Tab long-acting 150 mg Enoxaparin Sodium Inj 20 mg per 0.2 ml H 1%
10
1,552,178
$151,803
$0.0978
C H
1%
441,197
$249,806
$0.5662
C H
1%
161,633
$62,229
$0.3850
*
C H
1%
11,839
$65,115
$5.5000
*
C H
1%
373,841 7,180,541
$710 $1,378,664
$0.0019 $0.1920
*
C H C H
1% 1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Enoxaparin Sodium Inj 40 mg per 0.4 ml Inj 60 mg per 0.6 ml Inj 80 mg per 0.8 ml Inj 100 mg per ml, 1 ml Inj 120 mg per 0.8 ml Inj 150 mg per ml, 1 ml Gemfibrozil Cap 300 mg Tab 600 mg C H C H 1% 1%
Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
H H H H H H
1% 1% 1% 1% 1% 1%
Heparin Sodium Inj 1,000 iu per ml, 5 ml Inj 1,000 iu per ml, 35 ml Inj 5,000 iu per ml, 1 ml Inj 5,000 iu per ml, 5 ml Inj 25,000 iu per ml, 0.2 ml Heparinised Saline Inj 100 iu per ml, 5 ml Phosphate Supplement Tab 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg, effervescent Phytomenadione Inj 2 mg per 0.2 ml Inj 10 mg per ml, 1 ml Tab 10 mg Potassium Chloride Inj 75 mg per ml, 10 ml Inj 150 mg per ml, 10 ml Pravastatin Tab 10 mg Tab 20 mg Tab 40 mg Tab 80 mg $0.9153 $1.4193 $2.1770 C H C H C H C H 1% 1% 1% 1%
Not currently listed in the Pharmaceutical Schedule
1,243 6,482 7,384 16,955 5,207
$1,661 $78,432 $15,241 $46,965 $7,811
$1.3360 $12.1000 $2.0640 $2.7700 $1.5000 * *
C H C H C H C H C H
1% 1% 1% 1% 1%
3,900
$8,093
$2.0752
C H
1%
55,852
$41,889
$0.7500
C
6,441 2,520 57,915
$10,306 $4,642 $32,432
$1.6000 $1.8420 $0.5600
C H C H C H
1% 1% 1%
17,358 9,313
$9,026 $4,843
$0.5200 $0.5200
C H C H
1% 1%
Simvastatin Tab 10 mg 9,262,901 $2,572,308 $0.2777 C H 1%
There is a confidential rebate associated with simvastatin There is a confidential rebate associated with simvastatin
Tab 20 mg
44,310,135
$14,963,533
$0.3377
C H
1%
11
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Simvastatin Tab 40 mg 35,910,872 $21,546,523 $0.6000 C H 1%
There is a confidential rebate associated with simvastatin There is a confidential rebate associated with simvastatin
Units
Cost
Unit Subsidy
DV Limit
Comments
Tab 80 mg
2,077,816
$1,454,471
$0.7000
C H
1%
Cardiovascular System
Amiodarone Hydrochloride Inj 50 mg per ml, 3 ml Amlodipine Tab 2.5 mg Tab 5 mg Tab 10 mg Bendrofluazide Tab 1.25 mg Tab 2.5 mg Tab 5 mg Bumetanide Inj 500 mcg per ml, 4 ml Tab 1 mg Clonidine Inj 150 mcg per ml, 1 ml Tab 25 mcg Tab 150 mcg TDDS 2.5 mg, 100 mcg per day TDDS 5 mg, 200 mcg per day TDDS 7.5 mg, 300 mcg per day Felodipine Tab long-acting 2.5 mg Tab long-acting 5 mg Tab long-acting 10 mg Flecainide Acetate Cap long-acting 100 mg Cap long-acting 200 mg Inj 10 mg per ml, 15 ml Oral liq Tab 50 mg Tab 100 mg 252,342 264,329 $180,096 $333,187 $0.7137 $1.2605 622,030 465,021 17 $887,823 $1,172,318 $167 $1.4273 $2.5210 $9.8040 C H C H C H C H C H C H 1% 1% 1% 1% 1% 1%
Not currently listed on the Pharmaceutical Schedule
3,045
$18,526
$6.0840
C H
1%
C H 2,136,658 773,076 $559,163 $350,435 $0.2617 $0.4533 C H C H
1% 1% 1%
Not currently listed on the Pharmaceutical Schedule
C H 29,720,783 3,516,135 $802,461 $151,194 $0.0270 $0.0430 C H C H
1% 1% 1%
Not currently listed on the Pharmaceutical Schedule
$1.5900 702,728 $114,966 $0.1636
C H C H
1% 1%
7,106
$19,897
$2.8000
C H H
1% 1% 1% 1% 1% 1%
498,503
$151,196
$0.3033
C H H H H
7,868,000 13,936,666 9,447,736
$2,722,328 $2,554,591 $2,519,711
$0.3460 $0.1833 $0.2667
C H C H C H
1% 1% 1%
12
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Glyceryl Trinitrate Spray 400 mcg per dose Tab 600 mcg TDDS 5 mg TDDS 10 mg Isosorbide Mononitrate Tab 20 mg Tab long-acting 40 mg Losartan Tab 12.5 mg Tab 25 mg Tab 50 mg Tab 100 mg 1,884,413 48,255 $1,996,912 $56,941 $1.0597 $1.1800 1,390,462 $1,105,000 $0.7947 720,981 930,458 $129,777 $460,298 $0.1800 $0.4947 C H C H 1% 1% 203,467 84,047 $124,786 $68,641 $0.6133 $0.8167 27,874,641 $574,218 $0.0206 C H C H C H C H 1% 1% 1% 1%
Note this product has been recently discontinued
Units
Cost
Unit Subsidy
DV Limit
Comments
+ + + +
C H C H C H C H
1% 1% 1% 1%
There is a rebate associated with losartan Not currently listed in the Pharmaceutical Schedule There is a rebate associated with losartan There is a rebate associated with losartan
Losartan with Hydrochlorothiazide Tab 50 mg with hydrochlorothiazide 12.5 mg 401,260 $425,215 $1.0597
+
C H
1%
There is a rebate associated with losartan with hydrochlorothiazide
Methyldopa Tab 125 mg Tab 250 mg Tab 500 mg Metoprolol Succinate Tab long-acting 23.75 mg Tab long-acting 47.5 mg Tab long-acting 95 mg Tab long-acting 190 mg Mexiletine Hydrochloride Cap 50 mg Cap 200 mg Nifedipine Tab long-acting 30 mg Tab long-acting 60 mg Oxypentifylline Tab 400 mg Phentolamine Mesylate Inj 10 mg per ml, 1 ml Propafenone Hydrochloride Tab 150 mg 84,439 $69,071 $0.8180 C H 1%
13
118,665 591,604 145,971
$10,680 $75,725 $28,464
$0.0900 $0.1280 $0.1950
C H C H C H
1% 1% 1%
11,326,501 27,687,737 21,320,420 5,464,913
$1,962,883 $5,999,933 $7,958,913 $3,688,816
$0.1733 $0.2167 $0.3733 $0.6750
C H C H C H C H
1% 1% 1% 1%
120,285 84,220
$28,291 $46,363
$0.2352 $0.5505
C H C H
1% 1%
541,911 226,362
C H C H
1% 1%
51,359
$37,944
$0.7388
*
C H
1%
517
$1,858
$3.5940
*
C H
1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Quinapril Tab 5 mg Tab 10 mg Tab 20 mg Quinapril with Hydrochlorothiazide Tab 10 mg with hydrochlorothiazide 12.5 mg Tab 20 mg with hydrochlorothiazide 12.5 mg Trandolapril Cap 1 mg Cap 2 mg Tab 4 mg 36,268 46,194 $3,964 $7,308 $0.1093 $0.1582 * * C H C H C H 1% 1% 1%
Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
9,952,014 14,354,067 17,626,152
$783,224 $1,560,287 $2,525,828
$0.0787 $0.1087 $0.1433
C H C H C H
1% 1% 1%
2,116,789 5,351,415
$237,715 $815,021
$0.1123 $0.1523
C H C H
1% 1%
Triamterene with Hydrochlorothiazide Tab 50 mg with hydrochlorothiazide 25 mg Verapamil Hydrochloride Tab long-acting 120 mg 2,037,006 $123,850 $0.0608 C H 1% 488,921 $24,446 $0.0500 C H 1%
Dermatologicals
Acitretin Cap 10 mg Cap 25 mg Aqueous Cream Crm (100 g or less) C H 1%
This pack size is not currently listed in Section B of the Pharmaceutical Schedule
263,457 81,678
$249,626 $166,378
$0.9475 $2.0370
C H C H
1% 1%
Crm (greater than 100 g) Betamethasone Valerate Crm 0.1% Lotn 0.1% Oint 0.1% Betamethasone Valerate with Clioquinol Crm 0.1% with clioquinol 3% Oint 0.1% with clioquinol 3% Betamethasone Valerate with Fusidic Acid Crm 0.1% with fusidic acid 2% Calcipotriol Crm 50 mcg per g (pack size 30 g or less)
115,023,572
$540,611
$0.0047
C H
1%
4,498,594 219,295 1,436,315
$152,952 $44,078 $48,835
$0.0340 $0.2010 $0.0340
C H C H C H
1% 1% 1%
112,480 38,883
$26,174 $9,048
$0.2327 $0.2327
* *
C H C H
1% 1%
432,227
$100,579
$0.2327
*
C H
1%
1,339,336
$1,001,823
$0.7480
C H
1%
Volume is aggregated for all pack sizes of calcipotriol cream Volume is aggregated for all pack sizes of calcipotriol cream
Crm 50 mcg per g (pack size greater than 30 g)
1,339,336
$1,001,823
$0.7480
C H
1%
14
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Calcipotriol Oint 50 mcg per g (pack size 30 g or less) 1,509,702 $1,129,257 $0.7480 C H 1%
Volume is aggregated for all pack sizes of calcipotriol ointment Volume is aggregated for all pack sizes of calcipotriol ointment Volume is aggregated for all pack sizes of calcipotriol solution Volume is aggregated for all pack sizes of calcipotriol solution
Units
Cost
Unit Subsidy
DV Limit
Comments
Oint 50 mcg per g (pack size greater than 30 g)
1,509,702
$1,129,257
$0.7480
C H
1%
Soln 50 mcg per ml (pack size 30 ml or less)
340,124
$254,753
$0.7490
C H
1%
Soln 50 mcg per ml (pack size greater than 30 ml)
340,124
$254,753
$0.7490
C H
1%
Chlorhexidine Gluconate Soln 4% Clobetasone Butyrate Crm 0.05% (pack size 30 g or less) Crm 0.05% (pack size greater than 30 g) Clotrimazole Crm 1% Soln 1% Emulsifying Ointment Oint BP Fluorouracil Sodium Crm 5% Hydrocortisone Crm 0.5% (pack size greater than 100 g) Crm 1% (pack size 100 g or less) 15,744,933 $384,176 $0.0244 C H C H 1% 1%
Not currently listed in the Pharmaceutical Schedule Volume is aggregated for all pack sizes of hydrocortisone cream Volume is aggregated for all pack sizes of hydrocortisone cream
1,988,107
$28,629
$0.0144
C H
1%
800,150 669,433
$143,467 $120,029
$0.1793 $0.1793 *
C H C H
1% 1%
1,741,881 10,386
$47,902 $2,264
$0.0275 $0.2180 *
C H C H
1% 1%
32,769,451
$252,325
$0.0077
C H
1%
273,829
$327,089
$1.1945
*
C H
1%
Crm 1% (pack size greater than 100 g)
29,257,598
$713,885
$0.0244
C H
1%
Powder Hydrocortisone with Wool Fat and Mineral Oil Lotn 1% with wool fat hydrous 3% and mineral oil Ketoconazole Shampoo 2% Magnesium Sulphate Paste Miconazole Nitrate Crm 2% Lotn 2% Tincture 2% 1,284,360 18,085 35,417 $37,632 $2,628 $5,146 154,218 $5,737 3,350,447 $131,673 10,426,268 $414,965
$1.5056
C H
1%
$0.0398
C
$0.0393
C H
1%
$0.0372
*
C H
1%
$0.0293 $0.1453 $0.1453 * *
C H C H C H
1% 1% 1%
15
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Mometasone Furoate Crm 0.1% (pack size 30 g or less) 2,376,935 $627,511 $0.2640 C H 1%
Volume is aggregated for all pack sizes of mometasone furoate cream. There is a confidential rebate associated with mometasone Volume is aggregated for all pack sizes of mometasone furoate cream. There is a confidential rebate associated with mometasone Volume is aggregated for all pack sizes of mometasone furoate ointment. There is a confidential rebate associated with mometasone Volume is aggregated for all pack sizes of mometasone furoate ointment. There is a confidential rebate associated with mometasone There is a confidential rebate associated with mometasone
Units
Cost
Unit Subsidy
DV Limit
Comments
Crm 0.1% (pack size greater than 30 g)
2,417,520
$638,225
$0.2640
C H
1%
Oint 0.1% (pack size 30 g or less)
1,944,976
$513,474
$0.2640
C H
1%
Oint 0.1% (pack size greater than 30 g)
1,896,240
$500,607
$0.2640
C H
1%
Lotn 0.1%
239,341
$38,295
$0.1600
C H
1%
Oil in Water Emulsion Crm Podophyllotoxin Soln 0.5% Sunscreen Crm or Lotn 14,083 * C 19,467 $177,985 $9.1429 * C H 1% 35,021,248 $196,119 $0.0056 C H 1%
Tar with Triethanolamine Lauryl Sulphate and Fluorescein Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium Topical anti-acne treatment Lotn C
Sole supply could also be awarded for a gel, crm and/or liq preparation. This Line Item includes topical benzoyl peroxide, retinoid and tretinoin products. Not currently listed in the Pharmaceutical Schedule.
39,375,539
$181,127
$0.0046
C H
1%
Triamcinolone Acetonide Crm 0.02% Oint 0.02% 468,062 167,482 $30,190 $10,803 $0.0645 $0.0645 C H C H 1% 1%
Triamcinolone Acetonide with Gramicidin, Neomycin and Nystatin Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Urea Crm 10% 9,950,000 $250,740 $0.0252 C H 1% 518,437 269,242 $120,640 $53,848 $0.2327 $0.2000 * C H C H 1% 1%
16
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Wool Fat with Mineral Oil Lotn hydrous 3% with mineral oil 11,692,772 $65,480 $0.0056 * C H 1%
A range of pack sizes are required for this line item
Units
Cost
Unit Subsidy
DV Limit
Comments
Zinc Crm BP Zinc and Castor Oil Oint BP 9,645,382 $98,383 $0.0102 C 169,067 $2,215 $0.0131 * C H 1%
Extemporaneously Compounded Preparations and Galenicals
Acetylcysteine Inj 200 mg per ml, 10 ml Sodium Bicarbonate Powder BP $0.0240 C H 1% 388 $5,318 $13.7060 * C H 1%
Genito-Urinary System
Clotrimazole Pessaries 500 mg with applicator C H 1%
Not currently listed in the Pharmaceutical Schedule
Diaphragm Diaphragm Intra-Uterine Device IUD 8,414 $332,353 $39.5000 C
Sole supply may be awarded to a range of sizes
1,037
$44,487
$42.9000
C
Miconazole Nitrate Pessaries 100 mg Vaginal crm 2% with applicator Norethisterone with Mestranol Tab 1 mg with mestranol 50 mcg and 7 inert tab Oestriol Crm 1 mg per g with applicator Pessaries 500 mcg Papaverine Hydrochloride Inj 12 mg per ml, 10 ml 1,552 $22,696 $14.6240 C H 1% 1,508,863 256,243 $704,186 $123,842 $0.4667 $0.4833 C C 74,841 $5,897 $0.0788 * C 499,473 $34,364 $0.0688 * C H C H 1% 1%
Not currently listed in the Pharmaceutical Schedule
Hormone Preparations - Systemic Excluding Contraceptive Hormones
Cabergoline Tab 0.5 mg Calcitonin Inj 100 iu per ml, 1 ml Carbimazole Tab 5 mg 2,364,515 $255,368 $0.1080 C H 1% 690 $13,800 $20.0000 C H 1% 68,070 $893,759 $13.1300 C H 1%
17
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Desmopressin Inj 4 mcg per ml, 1 ml Inj 15 mcg per ml, 1 ml Nasal spray 10 mcg per dose Nasal drops 100 mcg per ml Fludrocortisone Acetate Tab 100 mcg Gestrinone Cap 2.5 mg Hydrocortisone Crm 0.5% (pack size 100 g or less) C H 1%
Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
1,911
$12,838
$6.7180
C H H
1% 1% 1% 1%
82,036 6,682
$414,282 $104,319
$5.0500 $15.6120
C H C H
830,319
$63,270
$0.0762
C H
1%
8,824
$112,363
$12.7338
C H
1%
Methylprednisolone Acetate Inj 40 mg per ml, 1 ml Methylprednisolone Acetate with Lignocaine Inj 40 mg per ml with lignocaine 1 ml Norethisterone Tab 5 mg Oestradiol Tab 1 mg Tab 2 mg TDDS 3.9 mg (releases 50 mcg of oestradiol per day) TDDS 7.8 mg (releases 100 mcg of oestradiol per day) TDDS 25 mcg per day TDDS 50 mcg per day TDDS 100 mcg per day Oestradiol valerate Tab 1 mg Tab 2 mg Oestradiol with levonorgestrel Tab 2 mg with 75 mcg levonorgestrel (36) and tab 2 mg oestradiol (48) Oestradiol with norethisterone Tab 1 mg with 0.5 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6) Oestriol Tab 2 mg 191,602 $44,701 $0.2333 C
18
5,595
$33,738
$6.0300
C H
1%
2,339
$14,104
$6.0300
C H
1%
1,246,493
$311,623
$0.2500
C H
1%
974,213 674,594 53,406 17,092 45,430 44,382 12,429
$143,307 $130,129 $55,008 $30,125 $17,091 $22,857 $10,952
$0.1471 $0.1929 $1.0300 $1.7625 $0.3762 $0.5150 $0.8812
* * * * * * *
C C C C C C C
211,560 387,803
$31,120 $74,807
$0.1471 $0.1929
*
C C
149,526
$28,844
$0.1929
C
1,148,192 536,350 325,257
$221,486 $103,462 $62,742
$0.1929 $0.1929 $0.1929
* * *
C C C
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Oestrogens Conjugated, equine tab 300 mcg Conjugated, equine tab 625 mcg Oestrogens with medroxyprogesterone Tab 625 mcg conjugated equine (28) and 5 mg medroxyprogesterone acetate tab (28) Tab 625 mcg conjugated equine (28) and 2.5 mg medroxyprogesterone acetate tab (28) Pamidronate Disodium Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Inj 9 mg per ml, 10 ml Prednisone Tab 1 mg Tab 2.5 mg Tab 5 mg Tab 20 mg Testosterone Cypionate Inj long-acting 100 mg per ml, 10 ml Testosterone Enanthate Inj long-acting 250 mg - prefilled syringe Testosterone Esters Inj 250 mg per ml, 1 ml Testosterone Undecanoate Cap 40 mg Tetracosactrin Inj 250 mcg Inj 1 mg per ml, 1 ml Triamcinolone Acetonide Inj 10 mg per ml, 1 ml Inj 10 mg per ml, 5 ml Inj 40 mg per ml, 1 ml 3,976 83 54,507 $8,835 $856 $306,220 $2.2220 $10.3100 $5.6180 C H C H C H 1% 1% 1% 142 227 $2,516 $6,102 $17.7180 $26.8800 C H C H 1% 1% 770,666 $779,760 $1.0118 C H 1% 11,936 $154,929 $12.9800 C H 1% 4,725 $70,875 $15.0000 C H 1% 446 $27,389 $61.4100 C H 1% 9,007,276 1,578,885 9,488,780 3,723,012 $178,344 $35,999 $210,651 $227,476 $0.0198 $0.0228 $0.0222 $0.0611 C H C H C H C H 1% 1% 1% 1% 50 4,717 323 $2,425 $318,398 $43,605 $48.5000 $67.5000 $135.0000 C H C H C H H 1% 1% 1% 1% 257,702 181,489 $49,711 $35,009 $0.1929 $0.1929 * * C C 1,207,489 1,896,813 $129,805 $279,021 $0.1075 $0.1471 * * C C Units Cost Unit Subsidy DV Limit Comments
Infections - Agents for Systemic Use
Amoxycillin Drops 125 mg per 1.25 ml Inj 250 mg Inj 500 mg Inj 1 g 266,390 714 1,884 9,037 $96,566 $902 $2,724 $19,881 $0.3625 $1.2640 $1.4460 $2.2000 C H C H C H C H 1% 1% 1% 1%
19
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Amoxycillin Clavulanate Grans for oral liq amoxycillin 125 mg with potassium clavulanate 31.25 mg per 5 ml Grans for oral liq amoxycillin 250 mg with potassium clavulanate 62.5 mg per 5 ml Tab amoxycillin 500 mg with potassium clavulanate 125 mg Benzylpenicillin Sodium (Penicillin G) Inj 600 mg Cefazolin Sodium Inj 500 mg Inj 1 g Cefepime hydrochloride Inj 1 g, 15 ml Inj 2 g, 77 ml Cefotaxime Inj 500 mg Inj 1 g Inj 2 g Cefoxitin Sodium Inj 1 g Ceftazidime Inj 250 mg Inj 500 mg Inj 1 g Inj 2 g Ceftriaxone Sodium Inj 250 mg Inj 500 mg Inj 1 g Inf 2 g Cefuroxime Axetil Tab 250 mg Cefuroxime Sodium Inj 250 mg Inj 750 mg Inj 1.5 g Cephalexin Monohydrate Grans for oral liq 125 mg per 5 ml C H 1%
Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
13,450,940 16,854,482 14,266,399
$369,901 $800,588 $4,565,248
$0.0275 $0.0475 $0.3200
C H C H C H
1% 1% 1%
12,573
$8,789
$0.6990
C H
1%
1,767 5,298
$2,403 $9,854
$1.3600 $1.8600
C H C H
1% 1%
H H
1% 1%
H H H
1% 1% 1%
939
$9,142
$9.7360
C H
1%
H H H H
1% 1% 1% 1%
714 385 1,808 $1,536 $9,763 $3.9900 $5.4000
C H C H C H H
1% 1% 1% 1%
Note this product has been recently discontinued
6,897
$13,622
$1.9750
C H
1%
$2.0970 136 $653 $4.8000 $12.3600
C H C H C H
1% 1% 1%
20
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Cephalexin Monohydrate Grans for oral liq 250 mg per 5 ml C H 1%
Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
Ciprofloxacin Tab 250 mg Tab 500 mg Tab 750 mg Clindamycin Cap hydrochloride 150 mg Inj phosphate 150 mg per ml, 4 ml Co-Trimoxazole Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Dicloxacillin Cap 250 mg Cap 500 mg Grans for oral liq 125 mg per 5 ml Inj 500 mg Inj 1 g Doxycycline Hydrochloride Tab 50 mg Tab 100 mg Erythromycin Ethyl Succinate Grans for oral liq 200 mg per 5 ml Grans for oral liq 400 mg per 5 ml Erythromycin Lactobionate Inj 300 mg Inj 1 g Erythromycin Stearate Tab 250 mg Tab 500 mg Flucloxacillin Sodium Inj 250 mg Inj 500 mg Inj 1 g Fluconazole Cap 50 mg Cap 150 mg Cap 200 mg 134,602 56,232 17,684 $69,710 $219,305 $26,209 $0.5179 $3.9000 $1.4821 C H C H C H 1% 1% 1%
21
223,855 984,019 45,652
$40,764 $292,057 $31,468
$0.1821 $0.2968 $0.6893
C H C H C H
1% 1% 1%
353,481 1,384
$251,643 $26,919
$0.7119 $19.4500
C H C H
1% 1%
9,838,261 2,591,235
$116,091 $88,102
$0.0118 $0.0340
C H C H
1% 1%
37,318 78,509 53,795
$3,840 $12,530 $1,910
$0.1029 $0.1596 $0.0355 $1.0900 $1.5080
* * *
C H C H C H C H C H
1% 1% 1% 1% 1%
735,699 6,020,003
$71,142 $195,048
$0.0967 $0.0324
*
C H C H
1% 1%
6,876,661 3,819,134
$257,875 $213,872
$0.0375 $0.0560
C H C H
1% 1%
83 293
$1,178 $1,905
$14.1940 $6.5000
C H C H
1% 1%
245,762 168,288
$36,741 $50,318
$0.1495 $0.2990
* *
C H C H
1% 1%
56 2,142 44,171
$52 $2,335 $66,610
$0.9320 $1.0900 $1.5080
C H C H C H
1% 1% 1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Fusidic Acid Inj 500 mg sodium fusidate per 10 ml Gentamicin Sulphate Inj 10 mg per ml, 1 ml Powder Isoniazid Tab 100 mg with rifampicin 150 mg Tab 150 mg with rifampicin 300 mg Mebendazole Oral liq 100 mg per 5 ml Tab 100 mg Metronidazole Inj 500 mg, 100 ml Oral liq benzoate 200 mg per 5 ml Suppos 500 mg Suppos 1 g Minocycline Hydrochloride Cap 100 mg Tab 50 mg Norfloxacin Tab 400 mg Ornidazole Tab 500 mg Piperacillin Sodium with Tazobactrum Sodium Inf 2 g with tazobactam sodium 250 mg Inf 4 g with tazobactam sodium 500 mg Procaine Penicillin Inj 1.5 mega u Rifampicin Cap 150 mg Cap 300 mg Oral liq 100 mg per 5 ml Tab 600 mg Stavudine (d4T) Oral soln 1 mg per ml Teicoplanin Inj 200 mg Inj 400 mg H H 1% 1% $0.5038 40,762 102,692 99,786 19,728 $23,911 $125,654 $21,055 $75,229 $0.5866 $1.2236 $0.2110 $3.8133 C H C H C H C H 1% 1% 1% 1% 3,486 $33,187 $9.5200 C H 1% H H 1% 1% 141,338 $174,976 $1.2380 C H 1% 925,075 $297,319 $0.3214 C H 1% 679,262 1,893,729 $131,233 $182,745 $0.1932 $0.0965 * * C H C H 1% 1% 196,452 2,037 2,806 $49,113 $4,987 $9,347 $0.2500 $2.4480 $3.3310 * H C H C H C H 1% 1% 1% 1% 51,909 13,060 $7,542 $8,250 $0.1453 $0.6317 * * C H C H 1% 1% 21,858 94,249 $19,681 $169,243 $0.9004 $1.7957 C H C H 1% 1% 95 $163 $1.7120 C H H 1% 1% $12.8700 * C H 1% Units Cost Unit Subsidy DV Limit Comments
+
C H
1%
22
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Terbinafine Tab 250 mg Tobramycin Inj 40 mg per ml, 2 ml Powder Trimethoprim Oral liq Tab 300 mg Vancomycin Hydrochloride Cap 125 mg Cap 250 mg Inj 50 mg per ml, 10 ml Voriconazole Inj 200 mg Tab 50 mg Tab 200 mg Zidovudine (AZT) Cap 100 mg Inj 200 mg per ml, 20 ml Oral liq 10 mg per ml 176,034 $51,050 $0.2900 38,376 $111,290 $2.9000 H H H 1% 1% 1% 2,261 $10,627 $4.7000 C H C H C H 1% 1% 1%
Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
2,550,859
$1,275,430
$0.5000
C H
1%
36,689
$201,790
$5.5000
C H H
1% 1%
C H 1,090,902 $172,363 $0.1580 C H
1% 1%
+ + +
C H H C H
1% 1% 1%
Musculo-skeletal System
Allopurinol Tab 100 mg Tab 300 mg Auranofin Tab 3 mg Diclofenac Sodium Inj 25 mg per ml, 3 ml Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg Ibuprofen Tab 200 mg Tab 400 mg Tab 600 mg Indomethacin Cap 25 mg 353,454 $20,854 $0.0590 C H 1%
23
11,110,012 7,898,573
$254,419 $334,899
$0.0229 $0.0424
C H C H
1% 1%
13,022
$14,973
$1.1498
*
C H
1%
23,595 7,606 12,794 68,492 165,224
$56,628 $1,407 $2,840 $26,301 $105,082
$2.4000 $0.1850 $0.2220 $0.3840 $0.6360
C H C H C H C H C H
1% 1% 1% 1% 1%
15,751,556 711,101 190,872
$280,378 $25,386 $10,154
$0.0178 $0.0357 $0.0532 * *
C H C H C H
1% 1% 1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Indomethacin Cap 50 mg Cap long-acting 75 mg Suppos 100 mg Naproxen Tab long-acting 750 mg Tab long-acting 1,000 mg Orphenadrine Citrate Inj 30 mg per ml, 2 ml Tab 100 mg Probenecid Tab 500 mg Pyridostigmine Bromide Tab 60 mg Tenoxicam Inj 10 mg per ml, 2 ml Suppos 20 mg Tiaprofenic Acid Cap long-acting 300 mg Tab 300 mg 291,076 67,739 $19,589 $4,552 $0.0673 $0.0672 * * C H C H 1% 1% 83,861 10,459 $167,722 $5,543 $2.0000 $0.5300 C H C H 1% 1% 348,269 $119,526 $0.3432 C H 1% 307,760 $169,268 $0.5500 C H 1% 64 1,106,615 $205 $205,166 $3.2000 $0.1854 * C H C H 1% 1% 754,179 714,613 $150,836 $166,719 $0.2000 $0.2333 C H C H 1% 1% 861,816 638,272 48,678 $59,896 $84,890 $23,526 $0.0695 $0.1330 $0.4833 C H C H C H 1% 1% 1% Units Cost Unit Subsidy DV Limit Comments
Nervous System
Amantadine Hydrochloride Cap 100 mg Amisulpride Tab 50 mg Tab 100 mg Tab 200 mg Tab 400 mg C H C H C H C H 1% 1% 1% 1%
Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule
423,125
$337,146
$0.7968
C H
1%
Amitriptyline Tab 10 mg Tab 25 mg Tab 50 mg Benztropine Mesylate Tab 2 mg Bromocriptine Mesylate Tab 2.5 mg Tab 10 mg 351,803 41,602 $112,858 $50,280 $0.3208 $1.2086 C H C H 1% 1%
24
13,117,576 7,489,485 1,904,738
$393,527 $254,642 $99,046
$0.0300 $0.0340 $0.0520
C H C H C H
1% 1% 1%
967,710
$116,899
$0.1208
C H
1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Bupivacaine Hydrochloride with Adrenaline Inj 0.25% with 1:400,000 of adrenaline, 10 ml Inj 0.25% with 1:400,000 of adrenaline, 20 ml Inj 0.5% with 1:200,000 of adrenaline, 10 ml Inj 0.5% with 1:200,000 of adrenaline, 20 ml Bupivacaine Hydrochloride with Fentanyl Inj 0.125% with 2 mcg fentanyl per ml, 15 ml Inj 0.125% with 2 mcg fentanyl per ml, 20 ml Inf 0.125% with 2 mcg fentanyl per ml, 100 ml Inf 0.125% with 2 mcg fentanyl per ml, 200 ml Citalopram Hydrobromide Tab 20 mg Clomipramine Hydrochloride Tab 10 mg Tab 25 mg Clonazepam Inj 1 mg per ml, 1 ml Oral drops 2.5 mg per ml Tab 500 mcg Tab 2 mg Cyclizine Lactate Inj 50 mg per ml, 1 ml Desipramine Hydrochloride Tab 25 mg Diazepam Inj 5 mg per ml, 2 ml Rectal tubes 5 mg Rectal tubes 10 mg Tab 2 mg Tab 5 mg Tab 10 mg Dihydrocodeine Tartrate Tab long-acting 60 mg Doxepin Hydrochloride Cap 10 mg Cap 25 mg Cap 50 mg Cap 75 mg 1,804,270 2,181,009 685,643 337,838 $90,033 $91,384 $47,926 $37,128 $0.0499 $0.0419 $0.0699 $0.1099 * C H C H C H C H 1% 1% 1% 1% 4,918,209 $2,483,696 $0.5050 C H 1% 18,572 16,347 17,430 2,260,085 2,452,165 597,865 $34,321 $86,639 $112,877 $37,969 $49,043 $20,626 $1.8480 $5.3000 $6.4760 $0.0168 $0.0200 $0.0345 C H C H C H C H C H C H 1% 1% 1% 1% 1% 1% 198,131 $128,072 $0.6464 * C H 1% 77,903 $232,930 $2.9900 C H 1% 12,278 105,259 5,144,280 1,014,611 $22,984 $77,681 $282,421 $100,954 $1.8720 $0.7380 $0.0549 $0.0995 C H C H C H C H 1% 1% 1% 1% 290,050 1,871,532 $29,005 $97,320 $0.1000 $0.0520 C H C H 1% 1% 18,286,429 $2,285,804 $0.1250 C H 1% H H H H 1% 1% 1% 1% H H H H 1% 1% 1% 1% Units Cost Unit Subsidy DV Limit Comments
25
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Entacapone Tab 200 mg Gelatin Plasma Replacer Inf 3.5%, 500 ml bag Inf 4%, 500 ml bag Hyoscine (Scopolamine) Patches, 1.5 mg Hyoscine Hydrobromide Inj 400 mcg per ml, 1 ml Ketamine hydrochloride Inj 200 mg Inj 1 g Ketorolac Inj 10 mg per ml Tab 10 mg C H C H 1% 1%
Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
208,674
$269,189
$1.2900
C H
1%
H H
1% 1%
3,948
$18,871
$4.7800
*
C H
1%
7,387
$9,839
$1.3320
C H
1%
H H
1% 1%
Levodopa with Carbidopa Tab 100 mg with carbidopa 25 mg 3,539,914 $707,983 $0.2000 C H 1%
There is a rebate associated with levodopa with carbidopa There is a rebate associated with levodopa with carbidopa There is a rebate associated with levodopa with carbidopa
Tab 250 mg with carbidopa 25 mg
188,846
$108,586
$0.5750
C H
1%
Tab long-acting 200 mg with carbidopa 50 mg
1,893,158
$1,325,211
$0.7000
C H
1%
Lisuride Hydrogen Maleate Tab 200 mcg Methadone Hydrochloride Inj 10 mg per ml, 1 ml Metoclopramide Hydrochloride Inj 5 mg per ml, 2 ml Midazolam Tab 7.5 mg Mirtazapine Tab 15 mg Tab 30 mg Tab 45 mg C H C H C H 1% 1% 1%
Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule
216,716
$198,664
$0.9167
C H
1%
28,038
$145,798
$5.2000
C H
1%
214,702
$107,351
$0.5000
C H
1%
385,162
$39,980
$0.1038
*
C H
1%
Morphine Sulphate Inj 10 mg per ml, 1 ml Inj 20 mg per ml, 1 ml 191,366 $181,798 $0.9500 C H C H 1% 1%
Not currently listed on the Pharmaceutical Schedule 26
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Morphine Sulphate Inj 10 mg per ml 10 ml prefilled syringe Inj 30 mg per ml, 1 ml Inj 30 mg per ml 30 ml prefilled syringe Inj 50 mg per ml 50 ml prefilled syringe Inj 60 mg per ml 30 ml prefilled syringe Suppos 5 mg Suppos 10 mg Suppos 20 mg Suppos 30 mg Tab long-acting 10 mg Tab long-acting 30 mg Tab long-acting 60 mg Tab long-acting 100 mg Nefopam Hydrochloride Tab 30 mg Nitrazepam Tab 5 mg Nortriptyline Hydrochloride Tab 10 mg Tab 25 mg Ondansetron hydrochloride Inj 2 mg per ml, 2 ml Inj 2 mg per ml, 4 ml Orphenadrine Hydrochloride Tab 50 mg Paracetamol Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml Suppos 125 mg Suppos 250 mg Tab 500 mg Paracetamol with Codeine Tab paracetamol 500 mg with codeine phosphate 8 mg Pentastarch Plasma Expander Inf 10%, 500 ml bag Pergolide Tab 0.05 mg C H 1%
Not currently listed on the Pharmaceutical Schedule 27
Units
Cost
Unit Subsidy
DV Limit
Comments
H 74,863 $77,259 $1.0320 C H H H H $1.4783 44 108 3,232 812,089 388,097 193,966 257,132 $41 $183 $8,454 $146,176 $139,715 $139,656 $218,562 $0.9233 $1.6925 $2.6158 $0.1800 $0.3600 $0.7200 $0.8500 C H C H C H C H C H C H C H C H
1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1%
967,393
$251,522
$0.2600
C H
1%
813,433
$16,269
$0.0200
*
C H
1%
2,900,419 6,036,700
$147,921 $421,362
$0.0510 $0.0698
C H C H
1% 1%
H H
1% 1%
429,819
$54,888
$0.1277
C H
1%
117,913,035 119,028,006 74,760 82,289 169,011,852
$825,391 $868,904 $24,334 $51,513 $1,554,909
$0.0070 $0.0073 $0.3255 $0.6260 $0.0092
C H C H C H C H C H
1% 1% 1% 1% 1%
28,667,405
$928,824
$0.0324
C H
1%
H
1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Pergolide Tab 0.25 mg Tab 1 mg Pethidine Hydrochloride Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 1.5 ml Inj 50 mg per ml, 2 ml Pimozide Tab 2 mg Tab 4 mg Tab 10 mg 157,684 $46,422 $0.2944 $0.5890 C H C H C H 1% 1% 1%
Not currently listed in the Pharmaceutical Schedule
Units
Cost
Unit Subsidy
DV Limit
Comments
246,165 50,469
$174,777 $138,285
$0.7100 $2.7400
C H C H
1% 1%
26,804
$20,103
$0.7500 $0.8700
C H C H C H
1% 1% 1%
80,992
$67,709
$0.8360
Prochlorperazine Inj 12.5 mg per ml, 1 ml Suppos 5 mg Suppos 25 mg Tab 3 mg buccal Sertraline Tab 50 mg Tab 100 mg C C 1% 1%
Not currently listed in the Pharmaceutical Schedule Not currently listed in the Pharmaceutical Schedule
30,862 6,599 13,508 305,139
$46,015 $12,564 $33,878 $36,434
$1.4910 $1.9040 $2.5080 $0.1194
* * * *
C H C H C H C H
1% 1% 1% 1%
Streptokinase Inj 1,500,000 IU Inj 250,000 IU Sulpiride Tab 200 mg Tab 400 mg C H C H 1% 1%
Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule
H H
1% 1%
Temazepam Tab 10 mg Tetrabenazine Tab 25 mg Thioridazine Hydrochloride Tab 10 mg Tab 25 mg Tab 50 mg Tab 100 mg Tolcapone Tab 100 mg 172,413 $221,982 $1.2875 C H 1% 239,925 331,899 161,660 93,146 $18,330 $28,942 $19,141 $17,735 $0.0764 $0.0872 $0.1184 $0.1904 C H C H C H C H 1% 1% 1% 1% 117,065 $253,984 $2.1696 C H 1% 4,578,761 $144,689 $0.0316 C H 1%
28
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Tramadol hydrochloride Cap 50 mg Inj 50 mg per ml, 1 ml Inj 50 mg per ml, 2 ml Tab sustained release 100 mg Tab sustained release 150 mg Tab sustained release 200 mg Triazolam Tab 125 mcg Tab 250 mcg Trimipramine Maleate Cap 25 mg Cap 50 mg Zopiclone Tab 7.5 mg 12,087,924 $535,495 $0.0443 C H 1% 831,275 460,978 $45,720 $47,020 $0.0550 $0.1020 C H C H 1% 1% 1,614,028 2,530,217 $82,315 $103,739 $0.0510 $0.0410 C H C H 1% 1% H H H H H H 1% 1% 1% 1% 1% 1% Units Cost Unit Subsidy DV Limit Comments
Oncology Agents and Immunosuppressants
Anastrozole Tab 1 mg Azathioprine Inj 50 mg Bleomycin sulphate Inj 15,000 iu Calcium Folinate Inj 3 mg Inj 50 mg Inj 100 mg Inj 300 mg Inj 1 g Tab 15 mg Cyclophosphamide Inj 1 g Inj 2 g Daunorubicin Inj 20 mg Etoposide Phosphate Inj 100 mg (of etoposide base) Fludarabine phosphate Inj 50 mg Tab 10 mg H PCT 1% H PCT 1%
29
713,664
$3,484,108
$4.8820
*
+
C H
1%
$46.3300
*
C H
1%
H PCT 1%
$3.4200 125 $950 $7.6000
C H PCT 1% C H PCT 1% H PCT 1% H PCT 1% H PCT 1%
1,735
$11,085
$6.3890
C H PCT 1%
C H PCT 1% H PCT 1%
H PCT 1%
H PCT 1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Ifosfamide Inj 1 g Inj 2 g Letrozole Tab 2.5 mg Lomustine Cap 10 mg Cap 40 mg Mercaptopurine Tab 50 mg Mesna Tab 400 mg Tab 600 mg Methotrexate Inj 2.5 mg per ml, 2 ml Inj 25 mg per ml, 2 ml Inj 25 mg per ml, 20 ml Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Mitomycin C Inj 10 mg Inj 2 mg Octreotide (somatostatin analogue) Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml LAR 10 mg pre-filled syringe LAR 20 mg pre-filled syringe LAR 30 mg pre-filled syringe Paclitaxel Inj 30 mg Inj 100 mg Inj 150 mg Inj 300 mg Inj 600 mg Teniposide Inj 10 mg per ml, 5 ml Thalidomide Cap 50 mg H PCT 1%
30
Units
Cost
Unit Subsidy
DV Limit
Comments
H PCT 1% H PCT 1%
261,995
$1,279,060
$4.8820
*
C H
1%
H PCT 1% H PCT 1%
144,715
$272,412
$1.8824
C H PCT 1%
H PCT 1% H PCT 1%
99 3,556 151
$468 $32,786 $12,118
$4.7300 $9.2200 $80.2500 $33.0000 $150.0000
C H PCT 1% C H PCT 1% C H PCT 1% C H PCT 1% C H PCT 1%
H PCT 1% H PCT 1%
2,822 7,692 472 180 834 506
$24,551 $124,610 $37,666
$8.7000 $16.2000 $79.8000
C H C H C H C H C H C H
1% 1% 1% 1% 1% 1%
$319,050 $1,772.5000 $1,967,198 $2,358.7500 $1,493,333 $2,951.2500
H PCT 1% H PCT 1% H PCT 1% H PCT 1% H PCT 1%
H PCT 1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Vinblastine Sulphate Inj 10 mg $27.5000 C H PCT 1% Units Cost Unit Subsidy DV Limit Comments
Respiratory System and Allergies
Aminophylline Inj 25 mg per ml, 10 ml Budesonide Metered aqueous nasal spray, 50 mcg per dose Metered aqueous nasal spray, 100 mcg per dose Cetirizine Hydrochloride Oral liq 1 mg per ml Tab 10 mg Fexofenadine Hydrochloride Tab 30 mg Tab 60 mg Tab 120 mg Tab 180 mg 69,395 114,122 $15,059 $54,094 $0.2170 $0.4740 * * C H C H C H C H 1% 1% 1% 1%
Not currently listed on the Pharmaceutical Schedule Not currently listed on the Pharmaceutical Schedule
4,134
$10,616
$2.5680
C H
1%
4,652,037 23,644,628
$54,894 $307,380
$0.0118 $0.0130
* *
C H C H
1% 1%
1,962,144 7,882,071
$53,959 $290,848
$0.0275 $0.0369
C H C H
1% 1%
Ipratropium Bromide Aerosol inhaler, 20 mcg per dose CFC-free Nedocromil Aerosol Inhaler, 2 mg per dose CFC-free Promethazine Hydrochloride Inj 25 mg per ml, 2 ml Tab 10 mg Tab 25 mg Theophylline Tab long-acting 250 mg Tab long-acting 350 mg 1,201,057 295,820 $258,347 $86,616 $0.2151 $0.2928 C H C H 1% 1% 11,889 806,222 741,368 $19,141 $44,342 $66,723 $1.6100 $0.0550 $0.0900 * * C H C H C H 1% 1% 1% 797,876 $165,240 $0.2071 * C H 1% 13,660,343 $1,106,488 $0.0810 C H 1%
Sensory Organs
Acetazolamide Sodium inj 500 mg Tab 250 mg Aciclovir Eye oint 3% Atropine Sulphate Eye drops 1% Betaxolol Hydrochloride Eye drops 0.25% 84,599 $199,654 $2.3600 C H 1%
31
C H 338,087 $29,583 $0.0875 C H
1% 1%
Not currently listed in the Pharmaceutical Schedule
19,808
$165,199
$8.3400
C H
1%
74,531
$19,922
$0.2673
C H
1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Betaxolol Hydrochloride Eye drops 0.5% Bimatoprost Eye Drops 0.03% Brimonidine tartrate Eye Drops 0.2% Brinzolamide Eye Drops 1% Dexamethasone with Framycetin and Gramicidin Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml 823,461 $463,197 $0.5625 * C 110,115 $215,165 $1.9540 C H 1% 137,809 $246,678 $1.7900 C H 1% 75,320 $489,580 $6.5000 C H 1% 10,486 $15,729 $1.5000 C H 1% Units Cost Unit Subsidy DV Limit Comments
Dexamethasone with Neomycin and Polymyxin B Sulphate Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g Diclofenac Sodium Eye drops 1 mg per ml 28,705 $79,226 $2.7600 C H 1%
Single dose presentation would not be a DV Pharmaceutical
98,582 12,613
$88,724 $19,424
$0.9000 $1.5400
C C
Flumetasone Pivalate Ear drops 0.02% with clioquinol 1% Fusidic Acid Eye drops 1% Hypromellose Eye drops 0.3% Eye drops 0.5% Latanoprost Eye drops 50 mcg per ml Levocabastine Eye drops 0.5 mg per ml Lodoxamide trometamol Eye drops 0.1% Naphazoline Hydrochloride Eye drops 0.1% Pilocarpine Eye drops 0.5% Eye drops 1% Eye drops 2% Eye drops 2% single dose Eye drops 3% Eye drops 4% 7,891 28,487 86,403 587 1,063 30,993 $1,678 $6,153 $24,884 $938 $454 $13,575 $0.2127 $0.2160 $0.2880 $1.5975 $0.4273 $0.4380 * C C C C C C
32
126,618
$75,300
$0.5947
*
C
222,560
$200,304
$0.9000
*
C H
1%
839,852 53,081
$146,722 $6,333
$0.1747 $0.1193
C H C H
1% 1%
402,406
$3,138,767
$7.8000
*
C H
1%
113,594
$247,351
$2.1775
*
C H
1%
165,937
$144,531
$0.8710
C H
1%
92,914
$25,709
$0.2767
C H
1%
SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED
Chemical Name Line Item Pilocarpine Eye drops 6% Polyvinyl Alcohol Eye drops 1.4% Eye drops 3% Sodium Cromoglycate Eye drops 2% Sulphacetamide Sodium Eye drops 10% Travoprost Eye drops 0.004% 87,048 $678,974 $7.8000 C H 1% 38,809 C H 1% 411,262 $135,305 $0.3290 C 238,572 59,023 $57,567 $15,269 $0.2413 $0.2587 C C 5,074 $2,896 $0.5707 C Units Cost Unit Subsidy DV Limit Comments
Special Foods
Food Thickner Powder Protein Supplement Powder 297,677 $10,448 $0.0351 C
Sole supply could be awarded for a single or range of flavours from one supplier
1,724,917
C
33
Metadata
Title
Tender of Certain Pharmaceuticals
Abstract
In accordance with PHARMAC’s objective of securing for eligible people in need of pharmaceuticals,…
Page 1
Note
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.
